Gülay ERDOĞAN KAYHAN, Başak KAYHAN, Mehmet GÜL, Zeynal Mete KARACA

Dexmedetomidine improves ultrastructural view of renal damage and biochemical parameters during an experimental inflammatory bowel disease

Abstract Investigation of the effect of Dexmedetomidine (Dex) on inflammatory bowel diseases (IBD) induced renal damage by using an experimental model. IBD frequently cause reduction in renal function and renal failure. Since perioperative anesthesia and postoperative conditions in intensive care can cause acute kidney injury and reduction on renal function; deciding on a sedative and anesthetic agent without side effects would reduce IBD caused renal damage. We investigated histopathological, electron microscopic analyzes and antioxidant effects of Dex on kidney tissue during trinitrobenzene sulfonic acid (TNBS) induced damage in BALB/c mice at two different concentrations of Dex; 5μg/kg and 30μg/kg. Blood samples were collected to analyze creatinine levels. The levels of malondialdehyde (MDA) and activity of antioxidant enzymes glutathione (GSH) and superoxide dismutase (SOD) were measured in tissue homogenates. Histopathological and ultrastructural changes in kidney following TNBS induction were significantly reduced in Dex treatment groups. Administration of Dex significantly reduced creatinine levels. MDA levels were significantly reduced in Dex groups. Administration of Dex brought back GSH level to control level. Administration of Dex significantly 1.48 and 1.96 times increased SOD activity at 5μg/kg and 30 μg/kg, respectively. Dexmedetomidine treatment may have benefits to prevent IBD induced renal damage.

PDF

___

Shanuhan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology. 2001;120:62235.

Weber CR, Turner JR. Inflammatory bowel disease: is it really just another break in the wall? Gut. 2007;56:6-8.

Karlinger K, Györke T, Makö E, et al. The epidemiology and the pathogenesis of inflammatory bowel disease. Eur J Radiol 2000;35:154-67.

Koutroubakis I, Manousos ON, Meuwissen SG, et al. Environmental risk factors in inflammatory bowel disease. Hepatogastroenterology. 1996;43:38193.

Shih DQ, Targan SR. Immunopathogenesis of inflammatory bowel diseases. World J Gastroenterol. 2008;14:390-400.

KH Katsanos, EV Tsianos. The kidneys in inflammatory bowel disease. Annals of Gastroenterol. 2002;15:41-52.

Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Intl. 2012;81:442-8.

Martin E, Ramsay G, Mantz J, et al. The role of the a2-adrenoreceptor agonist dexmedetomidine in postsurgical sedation in the intensive care unit. J Intensive Care Med. 2003;18:29-41.

Mantz J, Jasserand J, Hamada S. Dexmedetomidine: new insights. Eur J Anesthesiol. 2011;28:3-6.

Dere K, Sucullu I, Budak ET, et al. A comparison of dexmedetomidine versus midazolam for sedation, pain and hemodynamic control, during colonoscopy under conscious sedation. Eur J Anesthesiol. 2010;27:648-52.

Taşdoğan M, Memiş D, Sut N, et al. Results of a pilot study on the effects of propofol and dexmedetomidine on inflammatory responses and intraabdominal pressure in severe sepsis. J ClinAnesth. 2009;21:394-400.

Kayhan Erdoğan G, Gül M, Kayhan B, et al. Dexmedetomidine ameliorates TNBS-induced colitis by inducing immunomodulator effect. J Surg Res. 2013;183:733-41.

Domi R, Huti G, Sula H, et al. From pre-existing renal failure to perioperative renal protection: the anesthesiologists dilemmas. Anest Pain Med. 2016;6:e32386.

Cho JS, Shim JK, Soh S, et al. Perioperative dexmedetomidine reduces the incidence and severity of acute kidney injury following valvular heart surgery. Kidney Int. 2016;89:693-700.

Martin A, MacDonald J, Moore J. Renal failure and its treatment. Anaesthesia and Intensive Care Medicine. 2015;16:267-74.

de Broe ME, Porter GA. Clinical Nephrotoxins Renal Injury from Drugs and Chemicals. Springer International Publishing, 2008.

Gu J, Sun P, Zhao H, et al. Dexmedetomidine provides renoprotection against ischemia-reperfusion injury in mice. Crit Care. 2011;15:R153.

Luo C, Yuan D, Yao W, et al. Dexmedetomidine protects against apoptosis induced by hypoxia/reoxygenation through the inhibition of gap junctions in NRK-52E cells. Life Sci. 2015;122:72-7.

Si YN, Bao HG, Xu L, et al. Dexmedetomidine protects againstischemia/ reperfusion injury in rat kidney. Eur Rev Med Pharmacol Sci. 2014;18:1843-51.

Fonseca I, Reguengo H, Almeida M, et al. Oxidative stress in kidney transplantation: malondialdehyde is an early predictive marker of graft dysfunction. Transplantation. 2014;97:1058-65.

Sahin T, Begeç Z, Toprak HI, et al. The effects of dexmedetomidine on liver ischemia-reperfusion injury in rats. J Surg Res. 2013;183:385-90.

Hancı V, Yurdakan G, Yurtlu S, et al. Protective effect of dexmedetomidine in a rat model of α-naphthylthiourea-induced acute lung injury. J Surg Res. 2012;178:424-30.

. Laudenbach V, Mantz J, Lagercrantz H, et al. Effects of alpha(2)-adrenoceptor agonists on perinatal excitotoxic brain injury: comparison of clonidine and dexmedetomidine. Anesthesiology. 2002;96:134-41.

Marangoni MA, Hausch A, Vianna PT, et al. Renal function and histology after acute hemorrhage in rats under dexmedetomidine action. Acta Cir Bras. 2007;22:291-8.

Frumento RJ, Logginidou HG, Wahlander S, et al. Dexmedetomidine infusion is associated enhanced renal function after thoracic surgery. J ClinAnesth. 2006;18:422-6.

Tan F, Chen Y, Yuan D, et al. Dexmedetomidine protects against acute kidney injury through downregulating inflammatory reactions in endotoxemia rats. Biomed Rep. 2015;3:365-70